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 Apoptosis is a finely regulated process that serves to determine the fate of cells in response to various stresses. One such stress 
is DNA damage, which not only can signal repair processes but is also intimately involved in regulating cell fate. In this review 
we examine the relationship between the DNA damage/repair response in cell survival and apoptosis following insults to the 
DNA. Elucidating these pathways and the crosstalk between them is of great importance, as they eventually contribute to the etio­
logy of human disease such as cancer and may play key roles in determining therapeutic response. This article is part of a Special 
Issue entitled “Apoptosis: Four Decades Later”.
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Cell death is a fundamental cellular response that 
has a pivotal role in development as well as maintain-
ing tissue homeostasis �y eliminating unwanted cells. 
It is composed of �oth controlled and uncontrolled 
mechanisms� including apoptosis� autophagy� and 
necrosis. Apoptosis is a regulated cell death process 
that reflects the cellular decision to die in response 
to cues from the environment and is executed �y in-
trinsic cellular machinery [�� �]. In contrast� necrosis 
is uncontrolled cell death �rought upon �y overwhelm-
ing stress. Lastly� autophagy is characterized �y self-
destruction starting with engulfment of cytoplasmic 
material �y the phagophore and sequestration of ma-
terial to the autophagic vacuoles� where they are even-
tually destroyed [�]. The type and strength of stimuli� 
tissue type� developmental stage of the tissue� and 
the physiologic cellular microenvironment determines 
which cell death process is undertaken [�]. 
The human �ody is continuously exposed to vari-
ous external and internal stresses� such as hypoxia� 
toxins� oxidative stress� and many others [����]. The 
a�ility of individual cells to adapt to these stresses 
is crucial for their survival. Alternatively� if too much 
damage has �een sustained� coordinated activation 
of cell death processes must occur to rid the �ody 
of cells that contain potential disease initiating muta-
tions. Thus� complex adaptation strategies such as cell 
cycle checkpoints� DNA damage response pathways� 
and programmed cell death have evolved to com�at 
these environmental and physiological threats [�]. 
In this review� we will focus on one of these stresses� 
DNA damage� as it relates to the cell death processes. 
Ultimately� im�alance �etween DNA damage/repair 
and activation/inactivation of these cell death pro-
cesses leads to carcinogenesis and may even alter 
tumor response to therapy.
APOPTOSIS
Apoptosis is a vital process of programmed 
cell death characterized �y distinct morphological 
characteristics and energy-dependent �iochemical 
mechanisms [�� �]. It is an integral component of vari-
ous homeostatic and defense processes including 
normal cell turnover� aging� proper development 
and functioning of the immune system� hormone 
dependent atrophy� em�ryonic development� and 
chemical-induced cell death [�]. Either too much 
or too little apoptosis leads to various disease condi-
tions including autoimmune and neurodegenerative 
disorders� ischemic damage� and cancer [�� 9���]. 
Thus� the a�ility to modulate the life and death of a cell 
has immense therapeutic potential and has �een the 
su�ject of intense research over the years. 
Apoptosis ultimately leads to a series of coordi-
nated and energy-dependent activation of a group 
of cysteine proteases — caspases [�� ����8]. This 
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leads to a cascade of events that link the initiating 
stimuli to cellular death �Fig. ��. Early apoptosis is cha-
racterized �y cell shrinkage� dense cytoplasm� tightly 
packed organelles� and pyknosis due to chromatin 
condensation [�� ��� �8� �9]. This is followed �y �ud-
ding which involves extensive plasma mem�rane �le�-
�ing� karyorrhexis and separation of cell fragments 
into apoptotic �odies [�� �9]. The apoptotic �odies 
are su�sequently phagocytosed �y macrophages� 
parenchymal cells� or neoplastic cells and degraded 
within phagolysosomes [�� ��� �9]. �ince apoptotic 
cells do not release their cellular content into the 
interstitial tissue and there are no inflammatory cyto-
kines produced� there are no inflammatory reactions 
associated with apoptosis [�� ��� �9]. 
The major apoptotic pathways include the extrinsic 
or death receptor pathway� the intrinsic or mitochon-
drial pathway� and the perforin/granzyme pathway that 
involves T-cell mediated cytotoxicity �Fig. ��. For this 
review we will focus �riefly on the extrinsic and intrinsic 
pathways. For a more in depth discussion� please refer 
to these excellent reviews [�� �6].
Extrinsic pathway 
As mentioned a�ove� the extrinsic apoptotic signal-
ing is mediated �y the activation of death receptors [�� 
��� ��]. The death receptors are cell surface recep-
tors that transmit apoptotic signals after �inding with 
specific activating ligands. Death receptors �elong 
to the tumor necrosis factor receptor �TNFR� gene 
superfamily� including TNFR-�� Fas/CD9�� and the 
TRAIL receptors DR-� and DR-�. They are characte-
rized �y cysteine rich extracellular su�domains which 
allow highly specific ligand recognition� su�sequent 
trimerization� and activation of the death receptor 
[��]. �u�sequent signaling is mediated �y the cy-
toplasmic part of the death receptor which contains 
a conserved sequence termed the death domain �DD�. 
Adapter molecules like Fas-associated death domain 
protein �FADD� or Tumor necrosis factor receptor 
type �-associated DEATH domain �TRADD� possess 
the same sequence which allows them to form the 
death inducing signaling complex �DI�C� and further 
propagate the signal [��� ��]. Another domain of the 
FADD� the death effector domain �DED�� sequesters 
procaspase-8 to the DI�C. Accumulation of procas-
pase-8 at the DI�C leads to autocatalytic activation 
due to autopreoteolysis. This su�sequently releases 
active caspase-8 which activates effector caspases 
resulting in cell death [�� ��� ��].
Intrinsic pathway
On the other hand� the intrinsic apoptosis pathways 
involve procaspase-9 which is activated downstream 
of mitochondrial proapoptotic events at the cytosolic 
death signaling protein complex� the apoptosome [�� 
��]. Disruption of the inner mitochondrial transmem-
�rane potential and permea�ility releases proapoptotic 
proteins from the mitochondrial intermem�rane space 
into the cytoplasm. The released proteins include 
Fig. 1. �ignaling events characteristic of apoptosis
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cytochrome c� which activates the apoptosome and 
therefore the caspase cascade [�� ��]. Dimerization 
of procaspase-9 molecules at the Apaf-� scaffold 
induces caspase-9 activation and su�sequent proteo-
lytic activation of the effector procaspases-�� -6� and 
-7 [�� ��]. These cleave protein su�strates� including 
procaspases� resulting in the mediation and amplifica-
tion of the death signal and eventually in the execution 
of cell death [�� ��].
There is significant crosstalk �etween the pathways 
and molecules in one pathway can influence the other 
[�� ��]. The pathways converge on the same execu-
tion route which is initiated �y the cleavage of caspase 
� and results in DNA fragmentation� degradation 
of cytoskeletal and nuclear proteins� cross-linking 
of various proteins� formation of apoptotic �odies� 
expression of ligands for phagocytic cell receptors and 
phagocytosis [�]. Ultimately� activation of caspases 
leads to an irreversi�le cascade of events progressing 
towards cell death. 
As mentioned earlier� many cellular stresses can 
impact survival versus death pathways. In the next 
section� we focus on one particular cell stress� that 
is� DNA damage.
THE DNA DAMAGE RESPONSE
The human genome is under constant attack which 
leads to thousands of DNA lesions per day. The cellular 
response to DNA damage is critical for maintenance 
of genomic integrity [�� �� ��]. Dysregulation of this 
DNA damage response leads to genomic insta�ility� 
which can result in the inactivation of pro-apoptotic 
pathways and the survival of cells that are polyploid� 
contain damaged DNA� and have dysregulated telomere 
maintenance [�� �� ��� ��]. �uppression of the tightly 
regulated apoptotic process may thus play a critical 
role in the development of some cancers [�� �� 8� ��]. 
Com�ating this malignant transformation process 
is the DNA damage response� a complex mechanism 
to detect the a�ove mentioned lesions� signal their 
presence� and promote their repair. Additionally� 
mechanisms are in place such that if the damage 
is too great or repair is ineffective� activation of cell 
death pathways such as apoptosis or necrosis ensues 
�Fig. �� [�� 8� ��]. These steps are in place to com�at 
the threats posed �y excess or unrepaired DNA da-
mage [�� 8� ��]. In this next section� we �riefly discuss 
the different types of DNA damage and the cellular 
responses to such damage to ultimately regulate cell 
fate.
DNA can �e damaged �y exogenous agents such 
as radiation� x-ray� UV� alkylating agents� as well as �y the 
�y-products from endogenous processes such as reac-
tive oxygen and nitrogen species from meta�olism and 
errors from DNA replication [��8� ��]. The resultant 
DNA damage either involves one or �oth strands of the 
DNA �single strand vs. dou�le strand �reaks� respec-
tively�. While unresolved single strand �reaks ���Bs� 
can �e converted to dou�le strand �reaks �D�Bs� and 
repaired� unrepaired D�Bs can lead to severe conse-
quences in cells. D�Bs can �e mutagenic� since they can 
potentially affect the expression of multiple genes. Most 
importantly� as little as one unrepaired D�B can �e lethal 
to the cell [��8� ��].
Fig. 2. The complex relationship �etween DNA damage� repair 
and apoptosis. DNA damage triggers cellular responses such 
as cell cycle arrest� post-translational protein modifications� DNA 
repair� and transcription of pro/anti survival genes. The �alance 
�etween these processes ultimately determines cell fate
Exogenously� ultraviolet and other types of high en-
ergy radiation can induce ��Bs and D�Bs. UV-induced 
damage can also result in the production of pyrimidine 
dimers� where covalent cross-links occur in cytosine 
and thymine residues� disrupting DNA polymerases 
and preventing DNA replication [��8]. Other agents 
can form DNA adducts and inter/intra strand crosslinks 
which� if left unrepaired� can lead to permanent mu-
tations resulting in cell transformation and ultimately 
tumor development [��8].
Endogenously� oxidative DNA damage can occur 
and involves oxidation of specific �ases. 8-hydroxy-
deoxyguanosine �8-OHdG� is the most common marker 
for oxidative DNA damage [��8]. Oxidative stress plays 
a central role in the pathophysiology of age-induced 
apoptosis via accumulated free radical-induced dam-
age to the mitochondria. On the other hand� hydrolytic 
DNA damage involves deamination or the total removal 
of individual �ases. Loss of DNA �ases� known as AP 
�apurinic/apyrimidinic� sites� can �e particularly muta-
genic and if left unrepaired they can inhi�it transcription 
[7� ��]. Interestingly� hydrolytic damage may result 
from the overa�undance of reactive oxygen species� 
often a �yproduct of respiration. Of course� the type 
and severity of damage to the DNA dictate the cellular 
response and ultimately cell fate [��].
Regardless of the type of DNA damage� the re-
sponse to this insult involves sensing the damage� 
activating the checkpoints� and repairing/resolving the 
DNA lesions. These processes will �e discussed �elow.
DNA damage sensors
In order to initiate the DNA damage response� DNA 
damage sensors must first detect the a�errant DNA 
lesions. The Mre���Rad���N�s� �MRN� complex acts 
as the sensor of DNA damage and maintains genomic 
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sta�ility �y processing DNA ends and recruiting/�ridg-
ing other mem�ers of the DNA damage response [�� 
��� ��� �6��8]. �pecifically� Rad�� recognizes the 
DNA� N�s� recruits other DNA repair proteins to D�B 
lesions� and Mre�� processes the DNA ends with its 
DNA nuclease activity [�7]. This leads to activation 
of Ataxia Telangiectasia Mutated �ATM� or Ataxia Telan-
giectasia and Rad� Related �ATR� depending on where 
the damage resides �ATM: DNA D�Bs on chromatin vs. 
ATR: stalled replication forks� [�6� �9� ��]. It is at this 
point where a cascade of signaling events is orches-
trated to activate checkpoints and assem�le the re-
maining mem�ers of the DNA repair complex. 
Checkpoint activation
Upon sensing the DNA damage� a coordinated 
activation of DNA damage checkpoints as well as DNA 
repair proteins is required to arrest the cell cycle� thus 
allowing time for repair processes [��]. Checkpoints 
also induce changes in telomeric chromatin and 
recruitment of DNA repair proteins to sites of DNA 
damage� activation of transcription� telomere length� 
and induction of cell death �y apoptosis [��]. Not 
surprisingly� several checkpoint genes are essential 
for cell and organism survival. 
Chk�� a serine/threonine-protein kinase is required 
for checkpoint-mediated cell cycle arrest and activa-
tion of DNA repair in response to the presence of DNA 
damage or unreplicated DNA. Chk� �inds to and 
phosphorylates CDC�� which creates �inding sites for 
��-�-� proteins and triggers degradation of CDC�� via 
u�iquitination pathway and proteosomal degradation 
[��� ��]. This leads to increased inhi�itory tyrosine 
phosphorylation of CDK-cyclin complexes and �locks 
cell cycle progression. Chk� also �inds to Rad�� which 
promotes the release of Rad�� from BRCA�� increas-
ing the chromatin association of Rad�� and su�se-
quent HR-mediated DNA repair [��]. Chk� also pro-
motes repair of DNA cross-links �y phosphorylating 
FANCE which is required for the nuclear accumulation 
of FANCC and provides a critical �ridge �etween 
the FA complex and FANCD� [��]. Chk� also plays 
an essential role in maintenance of replication fork 
�y regulating PCNA [��]. Besides� it also plays a role 
�y modulating transcription of genes involved in cell-
cycle progression through phosphorylation of his-
tones and su�sequent epigenetic silencing of genes. 
Chk� phosphorylates R�� to promote its interaction 
with the E�F family of transcription factors trigger-
ing su�sequent cell cycle arrest and phosphorylates 
p�� activating the protein and promoting cell cycle 
arrest as well [��� ��].
Chk� functions similar to Chk�� regulating cell 
cycle checkpoint arrest through phosphorylation 
of CDC��� inhi�iting their activity [��� ����7]. In-
hi�ition of CDC�� phosphatase activity leads to in-
creased inhi�itory tyrosine phosphorylation of CDK-
cyclin complexes and �locks cell cycle progression. 
Chk� also phosphorylates NEK6 which is involved 
in G�/M cell cycle arrest [��]. �imilar to Chk�� 
Chk� regulates HR-mediated DNA repair through 
phosphorylation of BRCA�� enhancing the chromatin 
association of RAD��. Moreover� Chk� promotes the 
transcription of genes involved in DNA repair �including 
BRCA�� through the phosphorylation and activation 
of the transcription factor FOXM� [��]. Chk� also 
regulates apoptosis through the phosphorylation 
of p��� MDM� and PML [��� �6� �8]. Chk� mediated 
phosphorylation of p�� reverses inhi�ition �y MDM�� 
leading to accumulation of active p��. Chk� depen-
dent phosphorylation of MDM� also functions to re-
duce degradation of p��. The kinase also controls 
the transcription of pro-apoptotic genes through 
phosphorylation of the transcription factor E�F�. Fi-
nally� Chk� has a tumor suppressor role as well in that 
it functions in mitotic spindle assem�ly �y phosphory-
lating BRCA� and a�sence of Chk� has �een o�served 
in some cancers [��� ����8].
Cyclin dependent kinase �CDK� family of serine/
threonine kinases regulate cell cycle progression 
through phosphorylation of proteins that function 
at specific phases of the cell cycle [�6� �9]. Differ-
ent CDKs act at different phases of the cell cycle and 
their activity is each dependent on association with 
a mem�er of the cyclin family of proteins. Cdk�-cyclin 
B is important for the M phase transition while Cdk�-
cyclin E association is critical for G�/� transition. 
Cdk�-cyclin E also functions in the � and G� phases 
while CDK�-cyclin E and CDK6-cyclin D control 
progression through the G� phase of the cell cycle 
�y phosphorylation of the tumor suppressor protein� 
R� [�6� �9]. These proteins have thus �een actively 
studied for cancer therapy.
DNA repair pathways
Once the DNA damage has �een sensed and 
checkpoints activated� the process of repairing this 
damage is initiated. We will first focus on the D�B 
repair pathways� of which there are � major path-
ways: the homologous recom�ination �HR� and 
non-homologous end joining �NHEJ� [6�8� ��� ��]. 
HR relies on the presence of a sister chromatid and 
the cell cycle-regulated �`-to-�` resection of DNA ends 
that generates stretches of single stranded DNA. This 
single stranded DNA is �ound �y replication protein 
A �RPA�. BRCA� su�sequently �inds Rad�� and pro-
motes its loading onto RPA coated single stranded 
DNA to produce a RAD��-single stranded DNA nu-
cleoprotein filament. RPA-coated ssDNA also leads 
to recruitment and activation of the checkpoint kinase 
ATR� which phosphorylates various targets� includ-
ing the downstream checkpoint kinase CHK�. This 
cascade of events promotes DNA strand invasion and 
su�sequent HR events. Because of the use of the ho-
mologous sister chromatid as template� HR is an error 
free repair pathway and the major mechanism utilized 
�y cells for repairing D�Bs and restarting stalled rep-
lication forks [8� �6]. 
On the contrary� the error-prone NHEJ involves 
connecting and resealing the two ends of DNA D�B 
without the need for sequence homology �etween the 
ends. Thus� this process is not dependent on the cell 
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cycle and is� in fact� active throughout all phases of the 
cell cycle. It involves among others� Ku 7�/8�� DNA 
protein kinase family of proteins [8� ��� ��]. 
It is not yet clear what dictates the choice of repair 
pathway. Research suggests that the choice �etween 
NHEJ or HR pathways depends on cell cycle stage; 
NHEJ is active throughout the cell cycle� and its activity 
increases as cells progress from G� to G�/M �G� < � 
< G�/M�. HR is nearly a�sent in G�� most active in the 
� phase� and declines in G�/M [7� 8� ��� ��]. The over-
all efficiency of NHEJ is higher than HR at all cell cycle 
stages. Cells usually utilize error-prone NHEJ as the 
major D�B repair pathway at all cell cycle stages� while 
HR is used primarily in the � phase. Reports also sug-
gest key repair players such as CtIP� BRCA�� Ku� and 
others to impact the choice of D�B repair �y control-
ling the initial events of D�B repair such as D�B end 
processing/resection [�����]. 
For ��Bs� different repair processes are utilized. 
Usually� the intact complementary strand can �e used 
as a template to repair the damaged strand via a variety 
of repair mechanisms like �ase excision repair �BER� 
to repair damage to a single �ase caused �y oxida-
tion� alkylation� hydrolysis� or deamination� nucleotide 
excision repair �NER� to repair �ulky� helix-distorting 
lesions such as pyrimidine dimers and photo-adducts� 
and mismatch repair �MMR� to corrects errors of DNA 
replication and recom�ination which may have resulted 
in mispaired ��ut undamaged� nucleotides [�� 7� 8� 
��]. Formation of ��Bs is closely linked to damaged 
�ases and their attempted repair. It is worth noting that 
D�Bs may form during the attempted repair of ��Bs 
[�� 7� 8� ��]. Interestingly� the chromatin structure may 
�e modulated to facilitate protein recruitment during 
repair [��]. Modifications of DNA-associated histone 
proteins maintain genomic sta�ility. Upon the induction 
of DNA damage� phosphorylation of histones dictates 
if repair is justified or apoptosis is warranted [��� �6]. 
It is truly amazing how a cell decides whether to pursue 
repair and when to a�ort repair to favor apoptosis.
In this next section� we will discuss various key 
players in the DNA damage response who also play 
vital roles in regulating apoptosis.
INTERSECTION BETWEEN DNA DAMAGE 
RESPONSE AND APOPTOSIS
DNA damage sustained from normal DNA repli-
cation/cell processes� stress� mitotic catastrophe� 
agents such as radiation� toxins� hormones� growth 
factors� cytokines� and drugs� and reactive oxygen 
species can induce apoptosis if left unrepaired [�� �� 
7� 8� ��]. Additionally� current DNA damaging agents 
used in therapies act to overwhelm cellular DNA repair 
capacity to activate cell death processes. For example� 
irradiation� a standard treatment modality for a num�er 
of cancers such as �rain� �reast� and prostate� as well 
as a variety of chemotherapeutic agents induce DNA 
damage leading to apoptosis [�� �� 7� 8� ��� �7]. Below� 
we will discuss several key players that intersect the 
DNA repair pathways with apoptotic pathways.
P53 and apoptosis
The tumor suppressor protein p�� has �een shown 
to mediate cellular stress responses in that p�� can 
initiate DNA repair� cell-cycle arrest� senescence and� 
importantly� apoptosis [��� �6� �8� ��� �8���]. These 
responses suppress tumor formation. Thus� it is not 
surprising that most tumors have p�� mutations [��]. 
p�� mediates DNA damage response �y stimulating 
the nuclear release of histone H�. Phosphorylation 
is one of the primary post-translational modifications 
of p�� and this increases its sta�ility. Various kinases 
such as ATM� Chk� and Chk� are responsi�le for the 
phosphorylation of p��. Other post-translational modi-
fications such as acetylation� u�iquitination� methy-
lation� sumoylation� and neddylation also regulates 
p�� protein sta�ility and transcriptional activation [�6� 
�8� ��� �8� ��� ��]. The E� u�iquitin ligase MDM� regu-
lates p�� activity �y �inding to its N-terminal transac-
tivation domain� thus preventing its interaction with 
other transcriptional factors. MDM� also induces 
nuclear export of p�� and targets it for proteasomal 
degradation [�6� �8� ��� �8� ��� ��]. In event of failed 
DNA repair p�� initiates apoptosis �y transactivating 
pro-apoptotic proteins such as BAX� BID� PUMA and 
NOXA which permea�ilizes the mitochondrial mem-
�rane and leaks the pro-apoptotic factors [�6� �8� ��� 
�8� ��� ��]. p�� stimulates the extrinsic and/or the 
intrinsic pathway depending on the DNA damage. 
p�� has �een reported to �ind to the outer mitochon-
drial mem�rane and antagonize the anti-apoptotic 
function of BCL� and BCL-XL. p�� represses the 
activity of BCL�� an anti-apoptotic protein involved 
in retaining the mitochondrial permea�ility� as well 
as survivin. Moreover� p�� also initiates apoptosis via 
proteins localized on the endoplasmic reticulum and 
plasma mem�rane such as DR�. p�� can also exert 
transcription independent effects on mitochondria 
mem�rane permea�ility �y activating the pro-apop-
totic protein BAX or �y neutralizing the anti-apoptotic 
proteins BCL� or BCL-XL [��� �6� �8� ��� �8� ��� ��]. 
Tumor cells possessing wild type p�� undergo 
apoptosis to a greater extent following DNA damage 
than cells that possess mutations in p��. DNA damage 
can also activate p��-independent apoptosis which 
may �e called upon especially in cases in which p�� are 
mutated. The p�� homologs p6� and p7� are involved 
in this response. Unlike mutations in p��� mutations 
in p7� do not predispose to tumor formation �ut do have 
an impact on the DNA damage response. p7� is also 
often overexpressed in cancer. As mentioned a�ove� 
in response to DNA lesions� ATM and/or ATR activate 
CHK� and CHK�� which in turn activate E�F� [�8]. This 
in turn stimulates transcription of the p7� gene� increas-
ing the levels of p7� protein. While p�� requires p6� and 
p7� to activate apoptosis� p7� is pro-apoptotic even 
in the a�sence of p��. p7�-induced apoptosis is me-
diated �y transcriptional upregulation of PUMA� which 
in turn induces mitochondrial translocation of BAX and 
cytochrome c release �discussed a�ove�. p7� also in-
duces mitochondrial dysfunction via NOXA. On the other 
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hand� p6� has the a�ility to suppress p7�-mediated 
apoptosis [��� �6� �8� ��� �8� ��� ��]. 
Nuclear factor-κB �NF-κB� also has a role in p��-
independent apoptosis. This transcription factor is gen-
erally anti-apoptotic and promotes survival. Activation 
of NF-κB in response to DNA damage is mediated 
�y �UMOylation and ATM-dependent phosphorylation 
of NEMO �NF-κB essential modulator�. Under some 
circumstances� however� NF-κB exhi�its pro-apoptotic 
activity. For instance� presence of excess reactive oxygen 
species can induce NFκB-mediated transcription of the 
FA� ligand� there�y stimulating apoptosis [��]. NF-κB in-
duces TNF-α production and su�sequent receptor-inter-
acting protein � �RIP�� autophosphorylation. In associa-
tion with NEMO� RIP� kinase promotes JNK�-mediated 
induction of IL-8 and recruits FADD to activate caspase 
8 which then induces apoptosis [��]. p��-independent 
apoptosis can also �e triggered �y BCL-� degradation 
and G�K� which is detailed in a later section [��].
BRCA1 and apoptosis
The tumor suppressor BRCA� plays an integral 
role in the maintenance of genomic sta�ility and 
modulates cellular response to DNA damage [�6��8]. 
It is involved in �oth the major DNA dou�le strand �reak 
repair pathways — HR and NHEJ [�6]. BRCA� func-
tions in a variety of cellular processes including chro-
matin remodeling� protein u�iquitination� DNA rep-
lication� DNA repair� regulation of transcription� cell 
cycle checkpoint control� and apoptosis [�6��8]. 
BRCA� function is regulated through diverse mecha-
nisms including transcription control� protein-protein 
interaction� and post-translational modification [�9� 
�6� �8� �9]. BRCA� is a nuclear-cytoplasmic shuttling 
protein and its function may �e regulated via active 
shuttling �etween the cellular compartments [�9� �6� 
�8� �9]. When nuclear� BRCA� controls high ﬁdelity 
repair of damaged DNA. In contrast� BRCA� has �een 
shown to enhance p��-independent apoptosis when 
cytoplasmic [�9� �6� �8� �9]. BRCA� contains two nu-
clear localization signals which target it to the nucleus 
via importin and two nuclear export sequences which 
transport it to the cytoplasm via the CRM�/exportin 
pathway [�9� �6� �8�6�]. 
As mentioned a�ove� BRCA� shuttling can also 
�e regulated via protein-protein interaction. The 
BRCA�-associated RING domain protein �BARD�� 
has �een shown to prevent CRM� dependent nuclear 
export of BRCA� �y �inding to and masking the 
BRCA� NE� located at the N-terminal RING domain. 
On the contrary� the BRCA� C-terminus �BRCT� do-
main has �een shown to play a crucial role in DNA 
damage-induced nuclear import of BRCA� through 
association with numerous other proteins� including 
p��� CtIP and BACH [��� �9� �6� 6�]. p�� seems 
to �e an important player in DNA damage induced 
BRCA� nuclear export since human �reast cancer 
cells with deﬁciency in p�� function exhi�it a�er-
rant BRCA� shuttling [�9]. Mutations that target the 
BRCT region of BRCA� have �een shown to exclude 
BRCA� from the nucleus �y �locking nuclear import. 
Thus� the critical region responsi�le for regulating 
the location of BRCA� appears to reside in the BRCT 
domain. Nuclear exclusion of BRCA� can �e thera-
peutically exploited with poly�ADP-ri�ose� polymerase 
�PARP� inhi�itors as well as other DNA damaging 
agents such as cisplatin [�9]. 
In addition to the repair of damaged DNA� 
BRCA� plays a role in apoptosis [6��6�]. �pecifically� 
overexpression of BRCA� induces apoptosis and the 
process has �een linked to DNA damage-induced 
BRCA� nuclear export and the c-Jun N-terminal ki-
nase pathway [6�]. BARD�� which �inds and masks 
the BRCA� nuclear export sequence to prevent 
BRCA� nuclear export� inhi�its this BRCA�-mediated 
apoptosis. Moreover� the apoptotic pathway stimu-
lated �y BRCA� is independent of p�� [�6� �9]. 
BRCA� has also �een reported to �e present 
in the mitochondria where it promotes BCL� mediated 
apoptosis. BCL�-mediated targeting of BRCA� to the 
endomem�ranes depletes BRCA� from the nucleus 
resulting in decreased HR-mediated repair [66� 67]. 
In addition� BCL� expression is low in BRCA�-asso-
ciated tumors [68]. 
DNA-dependent protein kinase (DNA PK) and 
apoptosis
The DNA-dependent protein kinase �DNA PK� plays 
a critical role in D�B repair and V�D�J recom�ination 
[69]. DNA PK plays a central role in the NHEJ pathway 
for D�B repair in mammalian cells via autophosphory-
lation events as well as its association with other DNA 
repair proteins such as BRCA� and Ku. Ku �inds to the 
DNA end and recruits DNA PK� sta�ilizing its �inding 
to DNA. This is followed �y �ridging of the �roken ends 
�y DNA PK to facilitate rejoining. DNA-PK also recruits 
and activates proteins involved in DNA end-processing 
and ligation. The coordinated assem�ly of Ku and 
DNA-PKcs on DNA ends is followed �y recruitment 
of the DNA ligase IV�XRCC� complex that is respon-
si�le for the rejoining step [�� 7� 8� ��� 69]. 
DNA PK is present at the telomere and cap chromo-
some ends� protecting them telomere and preventing 
chromosome end-to-end fusions. This interaction with 
telomerase helps to maintain telomere length as well 
[7�]. Recently� it was reported that poly�ADP-ri�ose� 
polymerase � �PARP�� interacts genetically with the 
DNA PK catalytic su�unit to prevent cancer �lympho-
ma� �y suppressing p�� mutation and telomere fusions 
[7�]. The role of PARP in DNA repair and apoptosis 
is discussed in a su�sequent section. 
DNA PK also plays a crucial role in triggering apop-
tosis in response to severe DNA damage or critically 
shortened telomeres [7�� 7�� 7�]. The a�ility to trigger 
apoptosis in the presence of unresolved DNA dam-
age is critical for preventing progression to cancer. 
In response to DNA damage� DNA PK phosphorylates 
p�� and triggers p��-dependent apoptosis. Converse-
ly� DNA PK undergoes proteasomal degradation later 
on in the apoptotic process which aids to suppress pro-
survival signals [7�]. The Ku7� su�unit of DNA-PK has 
�een shown to suppress apoptosis �y sequestering 
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Bax from mitochondria [7�]. Increased acetylation 
of cytoplasmic Ku7� disrupts the Ku7�-Bax interaction 
augmenting apoptosis [7�].
PARP and apoptosis
PARP is a family of proteins involved in a num-
�er of cellular processes including DNA repair and 
apoptosis [76]. PARP is predominantly located in the 
nucleus where it promotes BER-mediated DNA single 
strand �reak repair �y �inding to the DNA and induc-
ing a structural modification [77]. It also induces the 
synthesis of poly�ADP-ri�ose� �PAR� chains which 
acts as a signal for other DNA repair proteins. An early 
transient �urst of poly�ADP-ri�osyl�ation �PARylation� 
of nuclear proteins followed �y caspase-� mediated 
cleavage of PARP is required for apoptosis to pro-
ceed [8� 76�8�]. This inactivation of PARP prevents 
depletion of NAD �a PARP su�strate� and ATP� which 
are required for later events in apoptosis. PARylation 
plays diverse roles in many molecular and cellular 
processes� including DNA damage detection and 
repair� chromatin modification� transcription� cell 
death pathways� and mitotic apparatus function [76� 
77� 79�8�]. These processes are critical for genome 
maintenance� carcinogenesis� aging� inflammation� 
and neuronal function [8� 76�8�]. 
PARP-� interacts physically and functionally with 
various proteins involved in these DNA repair path-
ways� and recruits the repair proteins to sites of DNA 
damage such as XRCC-� in BER and DNA PK in NHEJ-
mediated repair. PAR� as covalent attachment of au-
tomodified PARP-� and PARP-�� acts to recruit repair 
proteins to sites of DNA damage [8� 7�� 76�78� 8�� 8�]. 
PARP dependent ��B repair and BRCA�- and 
BRCA�-dependent D�B repair has �een exploited for 
cancer therapy [6�8� 78� 8�]. As mentioned a�ove� 
BRCA� and BRCA� are tumor-suppressor proteins 
important for D�B repair �y HR� and mutation of the 
genes encoding these proteins causes predisposition 
to �reast and ovarian cancers. PARP inhi�itors have 
shown promising results in BRCA deficient tumors 
and other DNA repair deficient tumors in clinical trials 
when com�ined with other cytotoxic agents [8��87]. 
We and others have recently reported that the PARP 
inhi�ition induces apoptosis in a variety of cell types. 
We have shown that in conjunction with EGFR inhi�i-
tors� the PARP inhi�itor ABT-888 activates the intrinsic 
apoptotic pathway as evidenced �y cleavage of caspase 
� and 9 [78]. PARP inhi�itor treatment also induces 
phosphorylation of DNA PK and stimulates error-prone 
NHEJ-mediated repair in HR-deficient cells� resulting 
in cell death. PARP� catalytic activity possi�ly regulates 
NHEJ in the a�sence of HR and thus� deregulated NHEJ 
may explain the exquisite cytotoxicity of HR deficient 
cells to PARP inhi�itors [78� 88]. 
PARP� inhi�itor induces caspase-independent cell 
death as well. It causes mitochondrial depolarization� 
mitochondrial permea�ility transition and mitochon-
drial release of AIF which� upon release from the 
mitochondria� translocates into the nucleus� where 
it triggers nuclear DNA fragmentation [89� 9�]. Thus� 
PARP inhi�itors tilt cell death from necrosis to apop-
tosis in cancer cells [9�].
ATM/ATR and apoptosis
Defects in ATM are associated with cancers such 
as T-cell pro-lymphocytic leukemia� and B-cell chronic 
lymphocytic leukemia [6�8� 9�]. Defective ATM also 
predisposes to sporadic colon cancer in tumors with 
microsatellite insta�ility [9�]. Loss of ATM results 
in hypersensitivity to radiation and defect in cell cycle 
arrest [9�]. ATM is also involved in p7� mediated 
apoptosis [9�]. Radiation induces ATM-dependent 
c-A�l phosphorylation which then activates p7�. Upon 
commitment to apoptosis� caspases �cysteine aspartic 
acid proteases� are activated in a proteolytic cascade 
and ATM is cleaved �y a caspase-�-like apoptotic pro-
tease. This generates a truncated ATM protein devoid 
of kinase activity �ut still retaining its DNA �inding 
a�ility. This functions to prevent further DNA repair 
and propagation of DNA damage signaling [9�� 9�].
As mentioned �efore� ATR activates p�� in response 
to DNA damage �y phosphorylating p�� [�9� ��� �6� 
��]. In response to DNA damage� ATR also phosphory-
lates and activates Chk�� which in turn phosphorylates 
p�� and regulates cell cycle progression. ATR also 
mediates phosphorylation of BRCA� in response to UV 
[�9� ��� �6� ��]. Thus� these signaling pathways can 
converge on �oth p�� and BRCA� mediated apoptosis.
ATM/ATR also mediates BID phosphorylation� 
which is required for DNA damage-induced intra-
� phase checkpoint [96]. An intact BH� domain is re-
quired for apoptosis �ut not BID-mediated � phase 
effects. Thus the two functions may �e distinct. BID 
accumulates in �oth the nucleus and mitochondria 
following stress suggesting a possi�le role in DNA 
damage response. Furthermore� like ATM and ATR� 
BID localizes to the chromatin fraction of the nucleus 
following treatment with DNA-damaging agents [96].
Sirtuins (SIRT) and apoptosis
�irtuins ��IRT� are a family of histone deacetylases 
which also has a role in the maintenance of genomic 
sta�ility [97]. They also possess mono-ri�osyltransferase 
activity [97� 98]. �IRT have �een implicated in influencing 
aging and regulating transcription� apoptosis and stress 
resistance [99]. For instance� �IRT� can deacetylate vari-
ous factors linked to the repair of DNA damage� includ-
ing the Werner helicase and NB�� [�������]. A�sence 
of �IRT results in increased chromosomal a�errations 
and impaired DNA repair. In addition �IRTs are recruited 
to sites of DNA �reaks following DNA damage to avoid 
genomic insta�ility [���]. Thus� �IRTs regulate epigenetic 
silencing and chromatin modification.
�IRT�� the human �ir� homolog� acts as a negative 
regulator of the transactivation function of p�� �y �ind-
ing and deacetylating p��� there�y repressing apop-
tosis induced �y DNA damage [���� ���]. Persistent 
lesions keep PARP in an activated state and the 
nicotinamide produced �y the process inhi�its �IRT�. 
This leads to hyperacetylation and enhanced trans-
activation of p�� which in turn leads to increase in the 
transcription of pro-apoptotic genes and su�sequent 
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apoptosis. Besides p��� �IRT� can regulate other 
targets linked to cell death� including Ku7�� E�F� and 
TGF-β signaling [��6� ��7].
Another �IRT-mediated pro-survival pathway in-
volves the Forkhead �ox class O �FOXO� transcription 
factors which control the expression of genes involved 
in apoptosis such as Fas ligand� Bim� TRAIL� cyclin D� 
Gadd��� p�7/Kip�� Gadd��� Mn�OD. Akt phosphory-
lates FOXO factors in the presence of growth factors 
[��8� ��9]. This prevents their nuclear translocation. 
However� when the growth factor signaling is switched 
off� FOXOs are located in the nuclei and act as tran-
scription factors. Acetyltransferases� PCAF and p���/
CBP mediated acetylation silences the transcription 
factors. The transcriptional activity of FOXO� is re-
stored �y deacetylation carried out �y �IRT� which 
leads to resumption of gene transcription including 
DNA damage checkpoint genes. This increases the 
a�ility of FOXO to induce cell cycle arrest and resist oxi-
dative stress [97�99� ��6���9]. Thus �IRT promotes 
cell survival via transcriptional regulation. Moreover� 
the concerted action of �IRT� and �IRT� appear 
to inhi�it cell death �y maintaining mitochondrial NAD 
levels following stress [98� ���]. It should �e noted 
that although �IRT predominantly antagonize stress-
induced cell death pathways� �IRT� can also deacety-
late components of the NFκB complex� leading to in-
creased cell death� primarily senescence [98� ���].
Epidermal growth factor receptor (EGFR) and 
apoptosis
The epidermal growth factor receptor �EGFR� plays 
an important role in the development and progres-
sion of solid tumors. In addition� EGFR activation also 
mediates resistance to chemotherapy and radiation 
therapy [78� 88]. EGFR inhi�ition down-modulates 
survival pathways and shifts towards the proapoptotic 
Bcl-� expression and/or activation [���]. 
There are multiple inhi�itors of EGFR that are currently 
either used as a standard of care or are in clinical trials. 
Inhi�itors of the tyrosine kinase activity of EGFR compete 
with ATP for �inding to the tyrosine kinase pocket of the 
receptor. They have significant antitumor activity since 
the EGFR-TKIs �lock signaling �y �oth ERK and AKT 
pathways and induce apoptosis [���]. EGFR mediated 
apoptosis requires an active kinase �ut not EGFR auto-
phosphorylation sites� meaning the truncated receptor 
can generate the apoptotic signal. EGFR can activate 
Ras and the induction in apoptosis is due to impaired 
Akt activation. EGFR inhi�ition induces BIM expression 
via inhi�ition of the MEK-ERK pathway and BIM induc-
tion plays a key role in EGFR-TKI-induced apoptosis. 
Research suggests that �oth the PI�K-AKT-survivin 
and MEK-ERK-BIM pathways contri�ute independently 
to EGFR inhi�itor-induced apoptosis [������6].
The BH�-only protein PUMA �p�� upregulated 
modulator of apoptosis� plays an essential role in p��-
dependent and -independent apoptosis. PUMA medi-
ates apoptosis through the Bcl-� family proteins Bax/
Bak and the mitochondrial pathway [��7]. PUMA is also 
induced �y EGFR inhi�itors independent of p��. EGFR 
inhi�itors �lock phosphorylation of EGFR and inhi�it the 
PI�K/AKT pathway� which leads to increased expres-
sion of p7� and its �inding to the PUMA promoter and 
su�sequent transactivation [��8]. Thus� PUMA func-
tions as a critical mediator of EGFR inhi�itor-induced 
apoptosis� especially in head and neck cancer cells 
where EGFR inhi�itors are widely used. Moreover� p7�� 
p6�� and the PI�K/AKT pathway serve as key regulators 
of PUMA induction after EGFR inhi�ition [��9].
Recent evidence also suggests a key role of EGFR 
in �oth major DNA D�B repair pathways. �pecifically� 
EGFR �inds and activates DNA PK for NHEJ [���� 
���]. Additionally� EGFR inhi�itors have �een shown 
to attenuate DNA repair pathways. Interestingly� 
we recently reported that the EGFR inhi�itor cetux-
ima� reduced �oth NHEJ and HR in head and neck 
cancer cells and su�sequently induced a synthetic 
lethality with the PARP inhi�itor ABT-888 [78]. This 
enhanced cytotoxicity was associated with activation 
of the intrinsic apoptotic pathway [78]. This �rings 
forth the possi�ility that other DNA repair proteins may 
�e involved in the apoptotic response. We are actively 
investigating this avenue.
Glycogen synthase kinase 3 (GSK3) and apop-
tosis
Another important player in linking extracellular sig-
nals to DNA damage/repair and ultimately apoptosis 
is the glycogen synthase kinase � �G�K��. Phosphory-
lation of su�strates �y G�K� allows it to modulate key 
processes including cell structure� meta�olism� gene 
expression and apoptosis [���]. G�K� has the unique 
capacity to either increase or decrease the apoptotic 
threshold due to its opposing regulation of the two 
major apoptotic signaling pathways. G�K� promotes 
cell death caused �y the mitochondrial intrinsic 
apoptotic pathway� �ut inhi�its the death receptor-
mediated extrinsic apoptotic signaling pathway [���]. 
G�K� is involved in the apoptotic response following 
growth factor withdrawal� inhi�ition of the PI�K/Akt 
signaling pathway� DNA damage� ER stress� hypoxia/
ischemia� and oxidative stress [���]. Intrinsic apop-
totic signaling which is activated �y cell damage 
is promoted �y G�K� �y facilitation of signals that 
cause disruption of mitochondria and �y regulation 
of transcription factors that control the expression 
of anti- or pro-apoptotic proteins. These transcription 
factors include p�� which was discussed a�ove and 
cyclic AMP response element �inding protein �CREB� 
[���� ���]. G�K�β activity in the nucleus promotes 
p��-induced expression of Bax in response to DNA 
damage and inhi�its CREB� which can �lock the 
CREB-dependent expression of the anti-apoptotic 
protein Bcl-� [���]. G�K� can regulate p�� levels 
through the phosphorylation of the p��-regulating 
protein MDM� as well as �y directly interacting with 
p�� [���]. G�K� promotes p��-mediated transcrip-
tion of specific genes and regulates the intracellular 
localization of p�� [���]. p�� is also a�le to activate 
apoptosis independently of its transcription function 
�y acting directly on mitochondrial proteins� and 
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G�K�β �inds p�� in the mitochondria� which may 
contri�ute to p��-induced apoptosis [��6]. In the 
canonical Wnt signaling pathway� the transcriptional 
co-activator β-catenin promotes growth and survival� 
�ut phosphorylation of β-catenin �y G�K� targets it for 
proteosomal degradation there�y promoting apopto-
sis [���]. Activation of Wnt signaling inhi�its G�K� se-
lectively in the Wnt signaling protein complex� causing 
accumulation of β-catenin and its translocation to the 
nucleus where it interacts with the TCF/LEF transcrip-
tion factors to induce expression of pro-survival genes. 
G�K� phosphorylates heat shock factor-� �H�F-��� 
a pro-survival transcription factor to inhi�it its activity� 
there�y reducing expression of heat shock proteins� 
an action that can facilitate apoptosis [��7]. �ince 
G�K� is present in the mitochondria as well and there 
is a spike in G�K� levels following DNA damage� 
G�K� is uniquely positioned to regulate apoptosis.
Pro-apoptotic mem�ers of the Bcl-� family of pro-
teins such as Bax transmit the apoptotic signal to the 
mitochondria following phosphorylation �y G�K�. �tress 
such as DNA damage induces a conformational change 
in Bax that promotes its translocation from the cyto-
plasm to the mitochondria where it can �oth sequester 
anti-apoptotic Bcl-� family proteins and oligomerize 
within the mitochondrial mem�rane. This as well as phos-
phorlylation of the voltage-dependent anion channels 
�y G�K� disrupts the mitochondrial mem�rane potential 
and releases apoptotic proteins such as cytochrome 
c from the mitochondrial intermem�rane space into the 
cytoplasm. Cytochrome c in turn �inds to the protein 
apoptotic protease activating factor-� �APAF-��� ATP/
dATP� and procaspase-9 to form the apoptosome in the 
cytoplasm. This causes the activation of caspase-9� 
there�y triggering the activation of the caspase cascade 
as discussed a�ove [���� ���].
The extrinsic apoptotic pathway entails extracel-
lular ligands stimulating cell-surface death receptors 
that initiate apoptosis �y activating caspase-8� and this 
early step in extrinsic apoptotic signaling is inhi�ited 
�y G�K�. Examples of death receptors include p��� 
Fas� DR� and DR�. Cellular insults induce recep-
tor homo-trimerization followed �y the recruitment 
of cytoplasmic adaptor and effector proteins which 
activates the receptor. This complex su�sequently 
�inds to the cytoplasmic proteins FADD and procas-
pase-8 �or procaspase-��� to form the DI�C. DI�C 
formation can allow autoactivation of caspase-8� which 
then leads to the activation of effector caspases� pri-
marily caspases-�� -6� and -7 [���� ���]. This pathway 
is discussed in detail a�ove. Thus� G�K� modulates 
key steps in each of the two major pathways of apop-
tosis� �ut in opposite directions.
G�K�β knockout mice are em�ryonically lethal due 
to massive hepatocyte apoptosis� which demonstrates 
that G�K�β is an important inhi�itor of apoptosis [�7� 
���� ��8]. G�K� inhi�itors promote apoptosis induced 
�y stimulation of DD-containing receptors �ut provide 
protection from many other insults that induce apoptosis. 
For instance� we have previously reported that inhi�ition 
of G�K� using lithium and other chemical inhi�itors se-
lectively kill tumor cells such as gliomas and leukemia �ut 
protect normal tissues from radiation-induced toxicity. 
The mechanism involved enhanced NHEJ mediated D�B 
repair following IR in normal tissues �ut not cancer. �ince 
radiation cannot �e selectively delivered to cancer cells� 
it leads to many destructive cellular processes including 
apoptosis� genomic insta�ility� and autophagy. Cranial 
irradiation therapy is a standard method for treatment 
of �rain cancer �ut results in long term neurocognitive 
deficits� especially in children. Thus� treatment with 
G�K� inhi�itors may potentially improve the quality of life 
of cancer patients undergoing radiation treatment. �eve-
ral clinical trials have �een initiated to test the efficacy 
of lithium in neuroprotection during the treatment of �rain 
tumors �ut the trials are still at their infancy [�7� ���� ��8]. 
It is perplexing that inhi�ition of G�K� upregulates 
DNA repair exclusively in normal cells. A possi�le 
explanation may �e that G�K� is already maximally 
inhi�ited in the majority of cancer. p�� status may 
also play a role in determining cellular response 
to G�K� inhi�ition �ut further research is warranted 
in this avenue. Our la� is currently investigating the role 
of G�K� in DNA damage/repair and how this relates 
to G�K�-induced neuroprotection. 
CONCLUSION
A wide array of key players in the DNA damage re-
sponse also is also involved in the interplay �etween cell 
survival and apoptosis. Further research is necessary 
to decipher the mechanisms �y which cell fate is de-
termined. In this complex network� uncovering these 
mechanisms may allow for the understanding of certain 
diseases and the generation of more effective therapies.
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